BCL201
Total Payments
$1.5M
Transactions
9
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $102,372 | 2 | 0 |
| 2019 | $309,451 | 1 | 0 |
| 2018 | $332,654 | 3 | 0 |
| 2017 | $727,075 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 9 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IB DOSE ESCALATION STUDY OF BCL201 INCOMBINATION WITH IDELALISIB IN PATIENTS WITH FOLLICULAR LYMPHOMA FL AND MANTLE CELL LYMPHOMA MCL | Novartis Pharmaceuticals Corporation | $878,324 | 0 |
| A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $593,228 | 0 |
Top Doctors Receiving Payments for BCL201
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $1.5M | 9 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 0
- Transactions 9
About BCL201
BCL201 is a drug associated with $1.5M in payments to 0 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $102,372 was paid across 2 transactions to 0 doctors.
The most common payment nature for BCL201 is "Unspecified" ($1.5M, 100.0% of total).
BCL201 is associated with 2 research studies, including "A PHASE IB DOSE ESCALATION STUDY OF BCL201 INCOMBINATION WITH IDELALISIB IN PATIENTS WITH FOLLICULAR LYMPHOMA FL AND MANTLE CELL LYMPHOMA MCL" ($878,324).